"The U.S. Food and Drug Administration today approved the MemoryShape Breast Implant to increase breast size (augmentation) for use in women at least 22 years old and to rebuild breast tissue (reconstruction) in women of any age. The MemoryShape B"...
- Patient Information:
Details with Side Effects
In one reported incident of acute overdose with SOMAVERT (pegvisomant) during pre-marketing clinical studies, a patient self-administered 80 mg/day for seven days. The patient experienced a slight increase in fatigue, had no other complaints, and demonstrated no significant clinical laboratory abnormalities. In cases of overdose, administration of SOMAVERT (pegvisomant) should be discontinued and not resumed until IGF-I levels return to within or above the normal range.
Drug Abuse And Dependence
Available data do not demonstrate drug-abuse potential or psychological dependence with SOMAVERT. Radiolabeled pegvisomant does not cross the blood-brain barrier in rats.
SOMAVERT (pegvisomant) is contraindicated in patients with a history of hypersensitivity to any of its components. The stopper on the vial of SOMAVERT (pegvisomant) contains latex.
Last reviewed on RxList: 3/29/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Somavert Information
Somavert - User Reviews
Somavert User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.